Rappel de Acetaminophen (Paracetamol) Reagent (used with L3K Assay in conjunction with the Architect cSystem Analyser). An in vitro diagnostic medical device (IVD)

Selon Department of Health, Therapeutic Goods Administration, ce/cet/cette rappel concerne un dispositif en/au/aux/à Australia qui a été fabriqué par Abbott Australasia Pty Ltd Diagnostic Division.

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
  • ID de l'événement
  • Classe de risque de l'événement
    Class II
  • Date de mise en oeuvre de l'événement
  • Pays de l'événement
  • Source de l'événement
  • URL de la source de l'événement
  • Notes / Alertes
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notes supplémentaires dans les données
  • Cause
    The manufacturer, sekisui has investigated complaints related to the formation of crystals in the r2 reagent and/or shift of controls when left on board an automated analyser. during the investigation, it was determined that when the r2 reagent is exposed to the atmosphere for prolonged periods of time, on board an automated analyser, crystals may form. sekisui has identified the crystals form from a standard component of the reagent. the amount of time to crystalise is dependent on reagent usage, temperature, and length of time on board the analyser. abbott internal testing has shown that the crystal formation does not impact architect csystem instrument performance.
  • Action
    Abbott is advising users to only leave the reagent on board the analyser for a maximum of 8 days and has decreased the calibration interval to 24 hours. Additionally, Abbott is reducing the shelf life for all affected batches to nine (9) months. Any reagent with an expiry date of 09-2016 should be discarded and the expiry dates for other affected batches amended. Abbott is advising users there is no requirement to review previously generated results. This action has been closed-out on 03/02/2017.


  • Modèle / numéro de série
    Acetaminophen (Paracetamol) Reagent (used with L3K Assay in conjunction with the Architect cSystem Analyser). An in vitro diagnostic medical device (IVD)Sekisui List Numbers: 506-10 and 506-30Abbott List Number: 3R11-20Multiple lot numbers and expiry datesARTG Number: 224545
  • Manufacturer


  • Société-mère du fabricant (2017)
  • Commentaire du fabricant
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source